Latest Novartis News & Updates

See the latest news and media coverage for Novartis. We track all announcements, press releases, and industry mentions in real time, all in one place.

Novartis

Innovative medicines company

novartis.com

Headquarters: Basel, Switzerland
Company type: Public company
Number of employees: 80,000+

Last updated Today

Latest news about Novartis

In short: Novartis expanded its pipeline and US manufacturing despite first-quarter earnings pressure from generic competition and patent expirations.

Company announcements

June 11 Novartis

Novartis del-brax Phase I/II study meets primary endpoint in FSHD

The FORTITUDE study showed reductions in KHDC1L and creatine kinase levels with a consistent safety profile.

June 8 Novartis

Novartis shows Rhapsido efficacy in chronic inducible urticaria

Phase III RemIND met primary endpoints across three common CIndU subtypes, doubling complete responses versus placebo and supporting FDA sNDA and further global filings in 2026.

June 4 Novartis

Novartis reports Vanrafia slows IgAN kidney decline

Phase III ALIGN (2.5 years) shows ~34% slower eGFR decline and 38% proteinuria reduction; results published in The Lancet and underpin a 2026 approval submission.

June 1 Novartis

Novartis reports positive 144-week Scemblix data in newly diagnosed CML

Scemblix showed 15.2% higher MMR rate vs second-generation TKIs with fewer adverse events, supporting long-term use.

Media coverage

Yesterday Medscape

Remibrutinib Resolves Chronic Inducible Urticaria

Remibrutinib met its primary endpoints in achieving complete response criteria across the three most common subtypes of chronic inducible urticaria in...

Yesterday AD HOC NEWS

Novartis stock: G-BA certifies considerable additional benefit

Novartis records leadership change in Australia, receives positive G-BA assessment for a cancer drug and shows stable price development.

June 16 Fondsvermittlung Uhland

Novartis: Are Imitators Endangering an Important Business Segment?

Novartis has built a large business with radioligand therapies. Now the world's first copy of such a drug is in the starting blocks. What are the consequences?

June 15 BusinessLine

Novartis brings in its advanced-prostrate-cancer drug to India

Novartis launches Pluvicto, India's first approved radioligand therapy for advanced prostate cancer, enhancing precision ...

Never miss news about Novartis

Track Novartis and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Novartis competitors & trending companies

Browse news for competitors to Novartis and other trending companies.